Kidney Inflammation

A Kidney Disease Treated in the Gut

The evidence here reaches further than almost any other gut connection, because it has produced an approved medicine. Kidney inflammation covers several conditions where the immune system damages the filtering units. The most common worldwide is IgA nephropathy. Its cause was traced back to the gut, and the treatment that followed acts there and nowhere else.

Where the damaging antibody is made

IgA is an antibody the body produces in large quantities at mucosal surfaces, meaning the linings of the gut, airways and other places open to the outside world.

In IgA nephropathy, a faulty version of it is produced. Specific sugar molecules are missing from its structure, so the immune system treats it as foreign and forms clusters around it.

Those clusters travel in the blood and lodge in the glomeruli, the kidney's filtering units. Inflammation follows, then scarring, then loss of function.

The question was where the faulty antibody comes from. The answer turned out to be the gut, specifically Peyer's patches. These are clusters of immune tissue embedded in the wall of the small intestine, concentrated in the final stretch called the distal ileum. They're where immune cells are trained to produce IgA in the first place.

A drug built around that location

That gave researchers an unusual target. Instead of suppressing the immune system throughout the body, treat the patch of intestine where the problem starts.

Budesonide is a steroid that has been used for decades. Reformulated in a capsule designed to dissolve only in the distal ileum, it releases directly onto the Peyer's patches.

The design matters twice over. It concentrates the drug where the faulty antibody is made, and because the liver breaks budesonide down heavily on first pass, very little reaches the rest of the body.

Systemic steroids have been tested in this disease and produced mixed results alongside serious infections. This approach was built specifically to avoid that.

Source: Mucosal targeting in IgA nephropathy targeting the gut associated lymphoid tissue

What the trial found

The phase three trial randomised 364 patients with IgA nephropathy, 182 to each group, and followed them for two years. Treatment lasted nine months.

The main measure was kidney filtration rate averaged across the two years. The treated group came out 5.1 millilitres per minute per 1.73 square metres higher than placebo.

Protein leaking into the urine, which is the standard marker of ongoing kidney damage, fell by 41% relative to placebo when averaged between months 12 and 24.

Both results were highly statistically significant. On the strength of them, the drug received accelerated approval from the US regulator in December 2021, and it now appears in international kidney guidelines for people at high risk of progression.

That's a kidney disease whose approved treatment is a capsule engineered to act on a few centimetres of small intestine.

Source: Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results

What it does and doesn't settle

Two honest points belong here.

The treatment suppresses immune activity in the gut. It doesn't tell us that gut bacteria caused the disease, and it isn't a dietary finding. What it establishes is that the gut immune system is where this particular kidney disease is generated.

Protein leakage also tends to return after treatment stops, as it does with systemic steroids. The nine-month course isn't a permanent fix, and questions remain about repeat treatment and about people with more advanced kidney impairment.

What it changes is the framing. A condition diagnosed by kidney biopsy is now treated by targeting intestinal immune tissue, which makes the gut a legitimate part of kidney medicine rather than a fringe interest.

What this means for you

Blood or froth in the urine, swelling around the eyes or ankles, or high blood pressure at a young age need medical assessment, since kidney inflammation is diagnosed by blood, urine and sometimes biopsy. In addition, the research above traced the faulty antibody driving the commonest form of kidney inflammation to immune tissue in the small intestine, and a drug acting only there improved kidney function across two years. A varied, plant-rich diet supports the same gut bacteria that help train and settle that intestinal immune tissue. That's the same idea behind GutLab, everyday gut health starts with regularly feeding the microbiome a broad range of plant-rich ingredients.